


EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name **BELLU LUISA**
CF **BLL LSU 87A52 L093T**
E-mail **luisa.bellu@iov.veneto.it**

Nationality **Italian**

WORK EXPERIENCE

Dates **June 2024 – To date**
Name and address of employer **Radiation Oncology Unit
Veneto Institute of Oncology IOV – IRCCS, Padua (Italy).**
Type of business or sector **Radiation therapy**
Occupation or position held **Radiation Oncologist**
Main activities and responsibilities **Radiation therapy and clinical research on oncological patients with particular attention on brain and breast tumors**

Dates **November 2020 – May 2024**
Name and address of employer **Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital,
Rozzano (Milan, Italy)**
Type of business or sector **Radiation therapy**
Occupation or position held **Radiation Oncologist**
Main activities and responsibilities **Radiation therapy and clinical research on oncological patients with particular attention on brain tumors and haematological malignancies**

Dates **November 2022 - May 2024**
Name and type of organisation providing education and training **Humanitas University**
Type of business or sector **PhD Course in Molecular and Experimental Medicine –
Clinical and preclinical research on brain tumors**
Occupation or position held **PhD student**

Dates **March 2020 – October 2020**
Name and address of employer **Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital,
Rozzano (Milan, Italy)**
Type of business or sector **Radiation Therapy**
Occupation or position held **Fellow**
Main activities and responsibilities **Assistance in medical management on oncological patients with particular attention on brain tumors and haematological malignancies**

1.

Dates	May 2019 – Dicember 2019
Name and address of employer	Service of Neuro-oncology, Istitute du Cerveau et e la Moelle epinière (Laboratoire ICM), Hospital Pitié Salpêtrière Hospital, Sorbonne University, Paris (France)
Occupation or position held	Fellow
Main activities and responsibilities	Translational project on glioblastoma patients with metabolism specifically dependent on the oxidative phosphorylation (OXPHOS +). Research project on glioma patients with BRAF mutation treated with BRAF/MEK inhibitor.
Dates	June 2019
Name and address of employer	Department of Radiation Therapy, Istitute Gustave Roussy Cancer Campus Paris (France)
Type of business or sector	Radiation Therapy
Occupation or position held	Fellow
Main activities and responsibilities	Assistance in clinical activity on brain tumors
Dates	November 2016 – November 2020
Name and type of organisation providing education and training	Padova University
Type of business or sector	Radiation Therapy
Occupation or position held	Resident in Radiation Therapy
Main activities and responsibilities	Assistance in medical management and clinical research in solid tumor.
Dates	January 2015 – October 2016
Name and address of employer	Medical Oncology 1 Unit Istituto Oncologico Veneto, IRCCS, Padova
Type of business or sector	Medical Oncology
Occupation or position held	Freelance Medical doctor with contract
Main activities and responsibilities	Assistance in medical management and clinical research in brain tumors and gastrointestinal tumours. Co-investigator for industry sponsored or non-sponsored trials dealing with brain tumours: SUPPORT trial RTOG 3508/AbbVie M13-813 EORTC protocol 1410-BTG/AbbVie protocol M14-483 Clinical Protocol BMS-936558 CA209548 Clinical Protocol BMS-936558 CA209498 EORTC protocol 1320-BTG Protocol OT-15-001 Orbus Therapeutics, Inc - STELLAR IOV-GB-1-2014 - REGOMA study.

2.

3.

5.

6.

1.

Dates	November 2011 - Dicember 2014
Name and address of employer	Medical Oncology 1 Unit, Istituto Oncologico Veneto, IRCCS, Padova
Occupation or position held	Fellow
Main activities and responsibilities	Research activitiy on Brain Tumours
EDUCATION AND TRAINING	
Dates	June 2022
Title of qualification awarded	Protection of animals used for scientific purposes; anesthesia, biological sampling, ethical suppression on mouse, rabbit, zebrafish.
Name and type of organisation providing education and training	Institute of Animal Technology (IAT) – Advancing and promoting excellence in the care and welfare of animals in science
Dates	October, 15 th 2013
Title of qualification awarded	Degree in Medicine (M.D.-Medical Doctor)
Name and type of organisation providing education and training	Padova University
PERSONAL SKILLS AND COMPETENCES	
Mother Tongue	Italian
Other Language(S)	ENGLISH
Reading skills	excellent
Writing skills	excellent
Verbal skills	very good
Reading skills	FRENCH
Writing skills	Intermediate
Verbal skills	beginner
	intermediate
TECHNICAL SKILLS AND COMPETENCES	
	Management of cancer patients
	Conduction of clinical trials on brain tumours (phase II,III) with certificate for ICH GOOD CLINICAL PRACTICE E6 (R2)
	Researches in public databases
	Preclinical research on brain tumors
	<i>Office package</i>
MEMBERSHIP PROFESSIONAL SOCIETIES	ASSOCIAZIONE ITALIANA DI RADIOTERAPIA (AIRO) GRUPPO NEURONCOLOGICO AIRO - Member of the Council ASSOCIAZIONE ITALIANA DI NEURONCOLOGIA (AINO)

2.

3.

Page 3/8 - Curriculum vitae of

5.

4.

Bellu Luisa

6.

1.

SCIENTIFIC
PUBLICATIONS

ASSOCIAZIONE ITALIANA DI RADIOBIOLOGIA (AIRB) – Secretary
EUROPEAN ASSOCIATION OF NEURONCOLOGY (EANO)
EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY-ESTRO
EUROPEAN ORGANISATION RESEARCH TREATMENT CANCER (EORTC)

Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A, Zoccarato M, Parisi A, Padovan M, Maccari M, Cavallin F, **Bellu L**, Pasqualetti F, Ius T, Denaro L, Volpin F, Coppola M, Lonardi S, Lombardi G. Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience. *J Neurooncol.* 2025 Jun;173(2):449-456. doi: 10.1007/s11060-025-04992-4. Epub 2025 Mar 10. PMID: 40063186; PMCID: PMC12106581.

Bonù, M. L., Georgopoulos, A., Ramera, M., Andreuccetti, J., Guerini, A. E., Bozzola, A. M., Morelli, V., Balduzzi, J., Katica, M., Cefaratti, M., Granello, L., Triggiani, L., Buglione, M., Magrini, S. M., Marampon, F., Mondini, M., Parisi, S., Timon, G., **Bellu, L.**, ... Scorsetti, M. (2025). Microbiota Modulation of Radiosensitiveness and Toxicity in Gastrointestinal Cancers: What Radiation Oncologists Need to Know—A Review on Behalf of the Italian Association of Radiobiology (AIRB). *Current Issues in Molecular Biology*, 47(4), 265. <https://doi.org/10.3390/cimb47040265>

Bono BC, Grimi A, Di Toro AE, Ninatti G, Franzini A, Rossini Z, Tropeano MP, Navarria P, **Bellu L**, Simonelli M, Dipasquale A, Savini G, Levi R, Politi LS, Pessina F, Riva M. Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series. *Neurosurgery.* 2025 Jan 29. doi: 10.1227/neu.0000000000003365. Epub ahead of print. PMID: 39878484

Tropeano, M. P., Raspagliesi, L., Bono, B. C., Baram, A., Rossini, Z., Franzini, A., Navarria, P., Clerici, E., **Bellu, L.**, Simonelli, M., Scorsetti, M., Riva, M., Politi, L. S., & Pessina, F. (2024). Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. *Acta neurochirurgica*, 166(1), 196. <https://doi.org/10.1007/s00701-024-06090-2>

Franceschini, D., Franzese, C., Comito, T., Ilieva, M. B., Spoto, R., Marzo, A. M., Dominici, L., Massaro, M., **Bellu, L.**, Badalamenti, M., Mancosu, P., & Scorsetti, M. (2024). Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbirt) for medically inoperable lung and liver oligometastases from breast cancer. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*, 195, 110240. <https://doi.org/10.1016/j.radonc.2024.110240>

Dei, D., Lambri, N., Crespi, L., Brioso, R. C., Loiacono, D., Clerici, E., **Bellu, L.**, De Philippis, C., Navarria, P., Bramanti, S., Carlo-Stella, C., Rusconi, R., Reggiori, G., Tomatis, S., Scorsetti, M., & Mancosu, P. (2024). Deep learning and atlas-based models to streamline the segmentation workflow of total marrow and lymphoid irradiation. *La Radiologia medica*, 129(3), 515–523. <https://doi.org/10.1007/s11547-024-01760-8>

Lambri, N., Longari, G., Loiacono, D., Brioso, R. C., Crespi, L., Galdieri, C., Lobefalo, F., Reggiori, G., Rusconi, R., Tomatis, S., **Bellu, L.**, Bramanti, S., Clerici, E., De Philippis, C., Dei, D., Navarria, P., Carlo-Stella, C., Franzese, C., Scorsetti, M., & Mancosu, P. (2024). Deep learning-based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy. *Medical physics*, 10.1002/mp.17089. Advance online publication.

2.

3.

5.

6.

1.

<https://doi.org/10.1002/mp.17089>

Scorsetti, M., Navarra, P., Cozzi, L., Clerici, E., **Bellu, L.**, Franceschini, D., Marzo, A. M., Franzese, C., Torri, V., Reggiori, G., Lobefalo, F., Raspagliesi, L., Attuati, L., Pessina, F., Franzini, A., Picozzi, P., & Tomatis, S. (2023). Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform. *Radiation oncology* (London, England), 18(1), 28. <https://doi.org/10.1186/s13014-023-02216-5>

Lambri, N., Antonetti, S. L., Dei, D., **Bellu, L.**, Bramanti, S., Brioso, R. C., Carlo-Stella, C., Castiglioni, I., Clerici, E., Crespi, L., De Philippis, C., Galdieri, C., Loiacono, D., Navarra, P., Reggiori, G., Rusconi, R., Tomatis, S., Scorsetti, M., & Mancosu, P. (2023). Impact of the Extremities Positioning on the Set-Up Reproducibility for the Total Marrow Irradiation Treatment. *Current oncology* (Toronto, Ont.), 30(4), 4067–4077. <https://doi.org/10.3390/curroncol30040309>

Navarra, P., Pessina, F., Minniti, G., Franzese, C., Marini, B., D'agostino, G., Badalamenti, M., Raspagliesi, L., Reggiori, G., Lobefalo, F., Fariselli, L., Franceschini, D., **Bellu, L.**, Clerici, E., Pinzi, V., & Scorsetti, M. (2023). Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study. *Cancers*, 15(5), 1393. <https://doi.org/10.3390/cancers15051393>

Dei, D., Lambri, N., Stefanini, S., Vernier, V., Brioso, R. C., Crespi, L., Clerici, E., **Bellu, L.**, De Philippis, C., Loiacono, D., Navarra, P., Reggiori, G., Bramanti, S., Rodari, M., Tomatis, S., Chiti, A., Carlo-Stella, C., Scorsetti, M., & Mancosu, P. (2023). Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation. *Cancers*, 15(5), 1536. <https://doi.org/10.3390/cancers15051536>

Franceschini, D., Teriaca, M. A., Di Cristina, L., Vernier, V., Lo Faro, L., Franzese, C., Comito, T., Clerici, E., **Bellu, L.**, Dominici, L., Spoto, R., Massaro, M., Navarra, P., & Scorsetti, M. (2023). Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors. *The British journal of radiology*, 96(1144), 20220771. <https://doi.org/10.1259/bjr.20220771>

Franzese, C., Marini, B., Baldaccini, D., Badalamenti, M., Navarra, P., **Bellu, L.**, Franceschini, D., Comito, T., Clerici, E., Teriaca, M. A., Massaro, M., Di Cristina, L., Lo Faro, L., Tomatis, S., & Scorsetti, M. (2022). The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. *Journal of cancer research and clinical oncology*, 10.1007/s00432-022-04352-z. Advance online publication. <https://doi.org/10.1007/s00432-022-04352-z>

Navarra P, Baldaccini D, Clerici E, Marini B, Cozzi L, Franceschini D, Bertuzzi AF, Quagliuolo V, Torri V, Colombo P, Franzese C, **Bellu L**, Scorsetti M. Stereotactic body radiation therapy (SBRT) for lung metastases from sarcoma in oligometastatic patients: a phase 2 study. *Int J Radiat Oncol Biol Phys*. 2022 Aug 17:S0360-3016(22)03131-5. doi: 10.1016/j.ijrobp.2022.08.028. Epub ahead of print. PMID: 35987453.

Franzese C, Navarra P, **Bellu L**, Marzo, M. A., Clerici, E., Badalamenti, M., Baldaccini, D., Franceschini, D., Comito, T., Teriaca, A., D'agostino, G., Reggiori, G., Tomatis, S., & Scorsetti, M. Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with

2.

3.

5.

6.

Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2022;34(6):379-385.
doi:10.1016/j.clon.2021.12.021

Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Rudà R, Amoroso R, **Bellu L**, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Persico P, Casini B, Fassan M, Zagonel V, Lombardi G. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. *Cancers (Basel)*. 2022 May 13;14(10):2425. doi: 10.3390/cancers14102425. PMID: 35626029; PMCID: PMC9139569.

Navarria P, Pessina F, Clerici E, **Bellu L**, Franzese C, Franzini A, Simonelli M, Bello L, Santoro A, Politi LS, D'agostino GR, Casarotti A, Fernandes B, Torri V, Scorsetti M. Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. *Radiother Oncol*. 2021 Dec 22;167:89-96. doi: 10.1016/j.radonc.2021.12.019. Epub ahead of print. PMID: 34952000.

Pessina F, Navarria P, Clerici E, **Bellu L**, Franzini A, Milani D, Simonelli M, Persico P, Politi LS, Casarotti A, Fernandes B, Olei S, Sollini M, Chiti A, Scorsetti M. Role of ¹¹C Methionine Positron Emission Tomography (¹¹CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. J Clin Med. 2021 May 25;10(11):2313. doi: 10.3390/jcm10112313. PMID: 34070698.

Berzero G, Bellu L, Baldini C, Ducray F, Guyon D, Eoli M, Silvani A, Dehais C, Idbaih A, Younan N, Them LN, Gaillard S, Pasqualetti F, Lepage-Seydoux C, Sekkate S, Tresca P, Kas A, Gratieux J, Ammari S, Saragoussi E, Savatovsky J, Delattre JY, Hoang-Xuan K, Meyronet D, Villa C, Bielle F, Sanson M, Touat M, Di Stefano AL. Sustained Tumor Control With MAPK Inhibition in *BRAF* V600-Mutant Adult Glial and Glioneuronal Tumors. *Neurology*. 2021 Jun 4:10.1212/WNL.0000000000012330. doi: 10.1212/WNL.0000000000012330. Epub ahead of print. PMID: 34088874.

Pessina F, Navarria P, **Bellu L**, Clerici E, Politi LS, Tropeano MP, Simonelli M, Fornari M, Scorsetti M. Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. *Neurosurg Focus*. 2020 Dec;49(6):E10. doi: 10.3171/2020.9.FOCUS20704. PMID: 33260137

Navarria P, Pessina F, Franzese C, Loi M, **Bellu L**, Clerici E, Marco Marzo A, Simonelli M, Lorenzi E, Salvatore Politi L, Bello L, Fornari M, Rossini Z, Santoro A, Scorsetti M. The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. *Radiother Oncol.* 2021 Mar;156:49-55. doi: 10.1016/j.radonc.2020.11.022. Epub 2020 Nov 25. PMID: 33245946.

Caccese M, Padovan M, D'Avella D, Chioffi F, Gardiman MP, Berti F, Busato F, **Bellu L**, Bergo E, Zoccarato M, Fassan M, Zagonel V, Lombardi G. Anaplastic Astrocytoma: State of the art and future directions. Crit Rev Oncol Hematol. 2020 Sep;153:103062. doi: 10.1016/j.critrevonc.2020.103062. Epub 2020 Jul 17. PMID: 32717623

Roux, A., Tauziede-Espariat, A., Zanello, M., Peeters, S., Zah-Bi, G., Parraga, E., Edjlali, M., Lechapt, E., Shor, N., **Bellu, L.**, Berzero, G., Dormont, D., Dezamis, E., Chretien, F., Oppenheim, C., Sanson, M., Varlet, P., Capelle, L., Dhermain, F., Pallud, J., 2020. Imaging growth as a predictor of grade of malignancy and

1.

aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults. Neuro-Oncology. <https://doi.org/10.1093/neuonc/noaa022>

Lombardi, G.; Bergo, E.; Caccese, M.; Padovan, M.; **Bellu, L.**; Brunello, A.; Zagonel V. Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients. Cancers 2019 11, 1509.

Villani, V.; Fabi, A.; Tanzilli, A.; Pasqualetti, F.; Lombardi, G.; Vidiri, A.; Gonnelli, A.; Molinari, A.; Cantarella, M.; **Bellu, L.**; et al. A Multicenter Real-World Study of Bevacizumab in Heavily Pretreated Malignant Gliomas: Clinical Benefit Is a Plausible End Point? Future Oncology 2019, 15 (15), 1717–1727. <https://doi.org/10.2217/fon-2018-0826>.

Lombardi, G., De Salvo, G.L., Brandes, A.A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., Rizzato, S., **Bellu, L.**, Pambuku, A., Farina, M., Magni, G., Indraccolo, S., Gardiman, M.P., Soffiatti, R., Zagonel, V., 2019. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 20, 110–119.

Lombardi, G., Bergo, E., Del Bianco, P., **Bellu, L.**, Pambuku, A., Caccese, M., Trentin, L., Zagonel, V., 2018a. Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study. American Journal of Clinical Oncology 41.

Lombardi, G., Caccese, M., **Bellu, L.**, Pambuku, A., Bergo, E., Berti, F., Gardiman, M.P., Della Puppa, A., Denaro, L., Dal Pos, S., Zagonel, V., 2018b. Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. Anti-Cancer Drugs 29.

Evangelista L, Cuppari L, **Bellu L**, Bertin D, Caccese M, Reccia P, Zagonel V, Lombardi G., n.d. Comparison between 18f-Dopa and 18f-Fet Pet/Ct in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and our Experience. Curr Radiopharm. 2019 Jan 15.

E. Bergo, G. Lombardi, A. Pambuku, A. Della Puppa, **L. Bellu**, D. D'Avella, and V. Zagonel, 2016. Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art. BioMed Research International BioMed Research International, 11 pages.

Lombardi, G., Pambuku, A., **Bellu, L.**, Farina, M., Della Puppa, A., Denaro, L., Zagonel, V., 2017. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology 111, 94–102. <https://doi.org/10.1016/j.critrevonc.2017.01.018>

Lombardi, G., **Bellu, L.**, Pambuku, A., Della Puppa, A., Fiduccia, P., Farina, M., D'Avella, D., Zagonel, V., 2016. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Journal of Neuro-Oncology 128, 481–486. <https://doi.org/10.1007/s11060-016-2136-7>

Ferrari, L., Fontanella, C., Uccello, M., Pasquini, G., Bozzarelli, S., Filippi, R., Imperatori, M., Ferrara, D., Tomasello, G., Brunetti, O., Pietrantonio, F., **Bellu, L.**

2.

3.

6.

5.

1.

Lutrino, E.S., Melisi, D., Antonuzzo, L., Musettini, G., Cordio, S., Vivaldi, C., Rimassa, L., Aprile, G., 2015. L07Baseline characteristics and survival outcomes of advanced gastric cancer patients treated with two or more lines of chemotherapy: results from a large Italian cohort. *Annals of Oncology* 26, vi–vi. <https://doi.org/10.1093/annonc/mdv344.07>

Lombardi, G., Pace, A., Pasqualetti, F., Rizzato, S., Faedi, M., Anghileri, E., Nicolotto, E., Bazzoli, E., **Bellu, L.**, Villani, V., Fabi, A., Ferrazza, P., Gurrieri, L., Dall'Agata, M., Eoli, M., Della Puppa, A., Pambuku, A., D'Avella, D., Berti, F., Rudà, R., Zagonel, V., 2015b. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). *Journal of Neuro-Oncology* 125, 359–367. <https://doi.org/10.1007/s11060-015-1923-x>

Lombardi G., Vitale A., Lonardi S., **Bellu L.**, Pambuku A., Marsico V., Crivellari G., Aliberti C., Cillo U., Zagonel V., 2015. Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib Citation metadata. *Hepatoma Res* 1, 58–62.

Lombardi, G., Corona, G., **Bellu, L.**, Della Puppa, A., Pambuku, A., Fiduccia, P., Bertorelle, R., Gardiman, M.P., D'Avella, D., Toffoli, G., Zagonel, V., 2015a. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. *Oncologist* 20, 562–567. <https://doi.org/10.1634/theoncologist.2014-0266>

Lombardi, G., Pambuku, A., **Bellu, L.**, Della Puppa, A., Rumanò, L., Gardiman, M.P., Pomerri, F., Zagonel, V., 2013. Cisplatin and Temozolomide Combination in the Treatment of Supratentorial Anaplastic Ependymoma. *Chemotherapy* 59, 176–180.

Bellu Luisa



2.

3.

6.

CANDIDATURA CONSIGLIERE GRUPPO REIRRADIAZIONE

LETTERA PROGRAMMATICA

CANDIDATO BELLU LUISA

Mi chiamo Luisa Bellu, sono un Radioterapista Oncologo attualmente in servizio, in qualità di Dirigente Medico, presso l'Istituto Oncologico Veneto (IOV) sotto la direzione del Prof. M. Krenkli.

Ho svolto il mio corso di specializzazione sotto l'egida dell'Università Degli Studi di Padova, dedicando tuttavia un anno ad uno stage all'estero presso la Clinica Pitié Salpêtrière e presso l'Istituto Gustave Roussy di Parigi, e l'ultimo anno ad uno stage presso l'Istituto Clinico Humanitas di Rozzano.

Ho poi trascorso i successivi 4 anni e mezzo di attività lavorativa presso lo stesso Istituto Humanitas per poi rientrare allo IOV nell'ultimo anno dopo la vittoria del concorso di assunzione a tempo indeterminato.

Sin dai tempi della specializzazione ho nutrito forte interesse all'ambito della reirradiazione, vedendolo diventare, di anno in anno, sempre più impattante nella pratica clinica quotidiana.

Sebbene taluni aspetti siano stati chiariti dalla più recente e nobile letteratura, diversi altri rimangono a tutt'oggi nebulosi: corretta selezione del paziente con la più precisa diagnosi differenziale tra recidiva/progressione vs radionecrosi, timing più adeguato per un ritrattamento radiante, miglior dose/frazionamento/tecnica.

Già taluni trial clinici sono in corso, in alcuni dei quali sono già parte attiva (e.g. EORTC Legato Trial), ma al fine di creare robuste evidenze scientifiche in risposta ai quesiti ancora aperti, ritengo che la cooperazione tra i Centri per la realizzazione di ulteriori studi ad hoc sia di basilare importanza.

E' sulla base di questi presupposti e con questi fini che propongo la mia candidatura a consigliere del Gruppo Reirradiazione.

Allegato CV.

In fede

Dr. Bellu Luisa